18 eredmény a kulcsszóra: 'small cell lung cancer'
(2015) Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer,
N/A
mAb, Monoclonal antibody; MCF-7, Michigan Cancer Foundation-7 breast-cancer cell line; MDA-MB-231, Breast-cancer cell line; NSCLC, Non-small cell lung cancer; OEC- M1, Human
N/A
(2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clinical cancer research :
N/A
Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to
N/A
In non-small-cell lung carcinoma, the anti-sense transcript of the tumor suppressor in lung cancer 1 (TSLC1) RP11-713B9.1 was shown to be downregulated, and its functions as
N/A
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy. Vascular
N/A
Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with Stage I non-small- cell lung cancer. Interact Cardiovasc Thorac Surg
N/A
The correlation between primary tumor and bone metastasis in non-small cell lung cancer was investigated by Badalian et al, who demonstrated that KRAS mutational status
N/A
The efficacy and safety of bevacizumab in addition to platinum- based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell
N/A
(2008) Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression.. Shedden
N/A
(2012) Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer
N/A
(2013) Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.. Tanizaki
N/A
radioimmunoassay, the tissue level of PACAP38-like immu- noreactivity (LI) and PACAP27-LI in different primary non- small cell lung cancer, colon tumor samples, and in cardiac
N/A
radioimmunoassay, the tissue level of PACAP38-like immu- noreactivity (LI) and PACAP27-LI in different primary non- small cell lung cancer, colon tumor samples, and in cardiac
N/A
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth
N/A
This is in contrast with small cell lung cancer cells, which were not affected by PI3K inhibition in their transmigration through brain microvascular endothelial cells.30 It has
N/A
specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.. Pooled analysis of the prognostic
N/A
Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer Chest, 2004, 126:
N/A